Eli Lilly and Company [NYSE: LLY] closed the trading session at $371.08 on 11/30/22. The day’s price range saw the stock hit a low of $361.80, while the highest price level was $372.35. The company report on November 30, 2022 that Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer’s Disease.
– Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm® (aducanumab-avwa)-treated patients at 6 months. - Donanemab reduced brain amyloid plaque levels vs. baseline by 65.2% compared with 17.0% for Aduhelm® at 6 months. The stocks have a year to date performance of 34.34 percent and weekly performance of 2.83 percent. The stock has been moved at 19.29 percent over the last six months. The stock has performed 2.48 percent around the most recent 30 days and changed 23.19 percent over the most recent 3-months. If compared to the average trading volume of 3.03M shares, LLY reached to a volume of 5530267 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Eli Lilly and Company [LLY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $380.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 18, 2022. While these analysts kept the previous recommendation, UBS raised their target price from $335 to $363. The new note on the price target was released on September 22, 2022, representing the official price target for Eli Lilly and Company stock. Previously, the target price had yet another raise to $341, while SVB Leerink analysts kept a Outperform rating on LLY stock. On April 06, 2022, analysts increased their price target for LLY shares from 265 to 364.
The Average True Range (ATR) for Eli Lilly and Company is set at 9.40, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 12.03. The Price to Book ratio for the last quarter was 33.19, with the Price to Cash per share for the same quarter was set at 2.89. Price to Free Cash Flow for LLY in the course of the last twelve months was 135.74 with Quick ratio for the last quarter at 0.90.
LLY stock trade performance evaluation
Eli Lilly and Company [LLY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.83. With this latest performance, LLY shares gained by 2.48% in over the last four-week period, additionally plugging by 19.29% over the last 6 months – not to mention a rise of 49.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 64.16, with the RSI for the last a single of trading hit 67.50, and the three-weeks RSI is set at 62.47 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 343.67, while it was recorded at 365.55 for the last single week of trading, and 310.33 for the last 200 days.
Eli Lilly and Company [LLY]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Eli Lilly and Company [LLY] shares currently have an operating margin of +26.65 and a Gross Margin at +74.18. Eli Lilly and Company’s Net Margin is presently recorded at +19.71.
Return on Equity for this stock inclined to 76.35, with Return on Assets sitting at 11.70.
Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.
Earnings per share (EPS) analysis for Eli Lilly and Company [LLY] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 19.14%.
Eli Lilly and Company [LLY]: Insider Ownership positions
There are presently around $294,468 million, or 84.80% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 103,773,810, which is approximately -0.372% of the company’s market cap and around 10.90% of the total institutional ownership; VANGUARD GROUP INC, holding 72,588,317 shares of the stock with an approximate value of $26.94 billion in LLY stocks shares; and BLACKROCK INC., currently with $23.5 billion in LLY stock with ownership of nearly -0.644% of the company’s market capitalization.
1,089 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 25,286,823 shares. Additionally, 1,036 investors decreased positions by around 22,873,776 shares, while 456 investors held positions by with 745,382,993 shares. The mentioned changes placed institutional holdings at 793,543,592 shares, according to the latest SEC report filing. LLY stock had 149 new institutional investments in for a total of 1,619,851 shares, while 88 institutional investors sold positions of 783,692 shares during the same period.